Evidence map›Paper›PMID 33473101›Full record

Trial reportSignal transduction and targeted therapy2021

Personalized neoantigen pulsed dendritic cell vaccine for advanced lung cancer.

Zhenyu Ding, Qing Li, Rui Zhang, Li Xie, Yang Shu, Song Gao, Peipei Wang, Xiaoqing Su, Yun Qin, Yuelan Wang and 13 more

Registry-linked trialOpen access · goldAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Signal transduction and targeted therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02956551 (Neoantigen-primed DC Vaccine Therapy for Refractory Non-small Cell Lung Cancer), which is not on this map. Cited by 181 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
181citing papers in PubMed, 2 pooled it
15.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02956551 phase1unknown statusnot on this map

Neoantigen-primed DC Vaccine Therapy for Refractory Non-small Cell Lung Cancer

TypeinterventionalSponsorSichuan UniversityRan2016 to 2020Enrolled20ConditionsCarcinoma, Non-Small-Cell LungArmsDC vaccine
3 · Its place in the literature

Who cites it

181 citing papers in PubMed, 2 syntheses or guidelines pooled it, 258 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Therapeutic vaccines for NSCLC: From mechanisms to clinical translation.Chinese medical journal pulmonary and critical care medicine · 2026
    Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. GM-CSF Promotes Superior In Vitro Differentiation of MHC IIInternational journal of molecular sciences · 2026
    Article
  20. Article

121 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 2 institutions in 1 country.

Zhenyu Ding *State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, and Collaborative Innovation Center for Biotherapy, Chengdu, 610041, China.
Qing Li *State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, and Collaborative Innovation Center for Biotherapy, Chengdu, 610041, China.
Rui Zhang *State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, and Collaborative Innovation Center for Biotherapy, Chengdu, 610041, China.
Li XieState Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, and Collaborative Innovation Center for Biotherapy, Chengdu, 610041, China.
Yang ShuState Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, and Collaborative Innovation Center for Biotherapy, Chengdu, 610041, China.
Song GaoDepartment of Oncology, Cancer Center, Shanghai Tenth People's Hospital, Tongji University, Shanghai, 200072, China.
Peipei WangState Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, and Collaborative Innovation Center for Biotherapy, Chengdu, 610041, China.
Xiaoqing SuState Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, and Collaborative Innovation Center for Biotherapy, Chengdu, 610041, China.
Yun QinDepartment of Radiology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Yuelan WangState Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, and Collaborative Innovation Center for Biotherapy, Chengdu, 610041, China.
Juemin FangDepartment of Oncology, Cancer Center, Shanghai Tenth People's Hospital, Tongji University, Shanghai, 200072, China.
Zhongzheng ZhuDepartment of Oncology, Cancer Center, Shanghai Tenth People's Hospital, Tongji University, Shanghai, 200072, China.
Xuyang XiaState Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, and Collaborative Innovation Center for Biotherapy, Chengdu, 610041, China.
Guochao WeiYuceBio Technology Co., Ltd, Shenzhen, China.
Hui WangDepartment of Oncology, Cancer Center, Shanghai Tenth People's Hospital, Tongji University, Shanghai, 200072, China.
Hong QianDepartment of Oncology, Cancer Center, Shanghai Tenth People's Hospital, Tongji University, Shanghai, 200072, China.
Xianling GuoDepartment of Oncology, Cancer Center, Shanghai Tenth People's Hospital, Tongji University, Shanghai, 200072, China.
Zhibo GaoYuceBio Technology Co., Ltd, Shenzhen, China.
Yu WangYuceBio Technology Co., Ltd, Shenzhen, China.
Yuquan WeiState Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, and Collaborative Innovation Center for Biotherapy, Chengdu, 610041, China.
Qing XuDepartment of Oncology, Cancer Center, Shanghai Tenth People's Hospital, Tongji University, Shanghai, 200072, China. xuqingmd@tongji.edu.cn.
Heng XuState Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, and Collaborative Innovation Center for Biotherapy, Chengdu, 610041, China. xuheng81916@scu.edu.cn.ORCID 0000-0002-7748-2621
Li YangState Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, and Collaborative Innovation Center for Biotherapy, Chengdu, 610041, China. yl.tracy73@gmail.com.
Sichuan University · CNTongji University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neoantigens are considered to be ultimate target of tumor immunotherapy due to their high tumor specificity and immunogenicity. Dendritic cell (DCs) vaccines based on neoantigens have exciting effects in treatment of some malignant tumors and are a promising therapeutic modality. Lung cancer is a lethal disease with the highest morbidity and mortality rate in the world. Despite the rapid development of targeted therapy and immune checkpoint inhibitors for lung cancer in recent years, their efficacy is still unsatisfactory overall. Therefore, there is an urgent unmet clinical need for lung cancer treatment. Here, we attempted to treat lung cancer using a personalized neoantigen peptide-pulsed autologous DC vaccine and conducted a single-arm, 2 medical centers, pilot study initiated by the investigator (ChiCTR-ONC-16009100, NCT02956551). The patients enrolled were patients with heavily treated metastatic lung cancer. Candidate neoantigens were derived from whole-exome sequencing and RNA sequencing of fresh biopsy tissues as well as bioinformatics analysis. A total of 12 patients were enrolled in this study. A total of 85 vaccine treatments were administered with a median value of 5 doses/person (range: 3-14 doses/person). In total, 12-30 peptide-based neoantigens were selected for each patient. All treatment-related adverse events were grade 1-2 and there were no delays in dosing due to toxic effects. The objective effectiveness rate was 25%; the disease control rate was 75%; the median progression-free survival was 5.5 months and the median overall survival was 7.9 months. This study provides new evidence for neoantigen vaccine therapy and new therapeutic opportunities for lung cancer treatment.

Indexed as

Antigens, NeoplasmCancer VaccinesDendritic CellsImmunotherapyLung NeoplasmsPrecision MedicineAgedAutograftsDisease-Free SurvivalFemaleHumansMaleMiddle AgedPilot ProjectsSurvival RateAntigens, NeoplasmCancer Vaccines

Identifiers

PMID33473101
PMCPMC7817684
OpenAlexW3123510155

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.